Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) completed a Pre-IND meeting with the FDA on Jan 6, 2026, securing regulatory alignment on its development approach for cell therapies.

The company said the FDA set a clear pathway toward an IND and the first-in-human (FIH) trial for ovarian cancer is expected in the second half of 2026. Tech transfer for clinical manufacturing is already underway to accelerate production of clinical-grade material and trial readiness.

Ernexa is advancing two allogeneic iMSC programs: ERNA-101 (ovarian cancer) and ERNA-201 (autoimmune disease), with initial clinical development focused on ERNA-101.

Positive

• FDA Pre-IND meeting provided regulatory alignment
• FIH trial for ovarian cancer targeted H2 2026
• Tech transfer for clinical manufacturing is underway
• Pipeline includes two allogeneic iMSC programs (ERNA-101, ERNA-201)

Negative

• IND submission remains pending before clinical dosing
• No clinical efficacy data reported yet for ERNA-101

News Market Reaction – ERNA

+4.96% 19.6x vol

9 alerts

+4.96% News Effect

+24.6% Peak Tracked

-13.5% Trough Tracked

+$497K Valuation Impact

$11M Market Cap

19.6x Rel. Volume

On the day this news was published, ERNA gained 4.96%, reflecting a moderate positive market reaction. Argus tracked a peak move of +24.6% during that session. Argus tracked a trough of -13.5% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $497K to the company's valuation, bringing the market cap to $11M at that time. Trading volume was exceptionally heavy at 19.6x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q3 2025 net loss: $1.24 million YTD 2025 net loss: $12.58 million Cash balance: $3.05 million +5 more

8 metrics

Q3 2025 net loss $1.24 million Quarter ended Sept 30, 2025 vs $26.60M prior year

YTD 2025 net loss $12.58 million Nine months ended Sept 30, 2025 vs $38.78M 2024

Cash balance $3.05 million As of Sept 30, 2025

Operating cash use $5.87 million Operating cash used year-to-date 2025

Private placement proceeds $7.20 million Gross proceeds from common stock and pre-funded warrant sales in 2025

Forward contract expense $5.85 million Non-cash forward sales contract expense tied to 2025 private placement

Shares outstanding 7,848,889 shares Common shares outstanding as of Nov 7, 2025

Phase 1 timing H2 2026 Targeted start of first-in-human trial for ERNA-101

Market Reality Check

Price: $0.2850 Vol: Volume 25,265 is 0.63x th...

low vol

$0.2850 Last Close

Volume Volume 25,265 is 0.63x the 20-day average 40,135, suggesting no outsized trading pressure. low

Technical Price 1.21 is trading below the 200-day moving average at 1.99, reflecting a longer-term downtrend.

Peers on Argus

Peers in Biotechnology show mixed moves (e.g., CELZ +2.0%, BOLT -4.07%, KZIA -3....

Peers in Biotechnology show mixed moves (e.g., CELZ +2.0%, BOLT -4.07%, KZIA -3.05%), indicating ERNA’s action around this news is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Preclinical data update	Positive	-1.5%	New ERNA-101 preclinical data showing strong immune activation and survival benefit.
Dec 03	Conference presentation	Positive	-4.2%	Announcement of oral ASH presentation on iMSC platform and ERNA-101 data.
Dec 02	Advisory board change	Positive	-4.0%	Appointment of leading gynecologic oncologist to strengthen clinical guidance.
Nov 11	Conference participation	Positive	-5.4%	Planned presentations on development, funding, and regulatory strategies at Cell 2025.
Nov 10	Operational update	Positive	-4.6%	Reported reduced operating loss and outlined IND and Phase 1 trial timelines.

Pattern Detected

Recent positive operational and data updates have been followed by negative 24h price reactions, indicating a pattern of bearish or fading responses to good news.

Recent Company History

Over the last few months, Ernexa has steadily advanced its iMSC platform toward first-in-human trials. Updates included conference presentations on ERNA-101’s preclinical data, strengthening of its scientific advisory board on Dec 2, 2025, and disclosures of IND-enabling timelines and a targeted Phase 1 start in H2 2026. Despite these seemingly positive milestones, each event saw negative 24-hour price reactions, contrasting with today’s constructive regulatory de-risking step.

Market Pulse Summary

This announcement reflects a key regulatory milestone, with a successful Pre-IND meeting and tech tr...

Analysis

This announcement reflects a key regulatory milestone, with a successful Pre-IND meeting and tech transfer supporting an H2 2026 first-in-human trial in ovarian cancer. Recent filings show a small cash balance of $3.05M and disclosures of substantial doubt about going concern, underscoring financing risk. Investors may watch for IND submission timing, trial start, and future capital raises as the company advances ERNA-101 toward the clinic.

Key Terms

pre-investigational new drug application, pre-ind, first-in-human, allogeneic, +4 more

8 terms

pre-investigational new drug application regulatory

"successful completion of its recent Pre-Investigational New Drug Application (Pre-IND) meeting"

A pre-investigational new drug application is an early meeting and written exchange between a drug developer and the regulatory agency to review plans before formally submitting an Investigational New Drug (IND) application. It matters to investors because it helps identify scientific, safety, manufacturing or data gaps early—like a rehearsal that can reduce the risk of costly delays or extra work and give a clearer idea of development timelines and regulatory hurdles.

pre-ind regulatory

"Pre-Investigational New Drug Application (Pre-IND) meeting with the U.S. Food and Drug Administration"

"Pre-ind" is short for "pre-indication" and refers to the period before a formal announcement or official signal that a significant change or event is about to happen, such as a company preparing to release important news. For investors, it can signal a time of increased activity or uncertainty, as market participants try to interpret hints and anticipate future developments. Recognizing pre-ind conditions helps investors make more informed decisions ahead of major shifts.

first-in-human medical

"on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

allogeneic medical

"two synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

induced mesenchymal stem cell medical

"two synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies"

An induced mesenchymal stem cell is a cell that has been converted in the lab from another cell type to behave like a natural mesenchymal stem cell, capable of becoming connective tissues (bone, cartilage, fat) and calming inflammation. Think of it as retraining a worker to perform a new, valuable job; for investors this matters because these lab-made cells are the basis for potential therapies, manufacturing and regulatory risk, intellectual property, and future revenue if safety and effectiveness are proven.

induced pluripotent stem cells medical

"Built from reprogrammed induced pluripotent stem cells (iPSCs), Ernexa’s engineered iMSCs"

Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, meaning they can become many different cell types. For investors, iPSCs matter because they are a flexible platform for developing new drugs, testing safety, and creating personalized therapies; think of them as blank building blocks that can be used to prototype treatments and reduce development risk before large clinical bets.

cytokines medical

"deliver potent therapeutic cytokines directly to the disease site"

Small proteins produced by immune and other cells that act as on/off signals or “text messages,” telling cells to ramp up, calm down, grow, or move during infection, injury, or disease. Investors watch cytokines because they are common drug targets and biomarkers—changes in cytokine activity can make a therapy work, cause serious side effects, or determine clinical trial and regulatory outcomes, all of which affect a company’s value.

u.s. food and drug administration regulatory

"meeting with the U.S. Food and Drug Administration (FDA)"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

AI-generated analysis. Not financial advice.

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness

Company on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half of 2026

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the successful completion of its recent Pre-Investigational New Drug Application (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA). Feedback from the FDA provided strong regulatory alignment on Ernexa’s development approach and set a clear pathway toward submitting the IND and initiating its first-in-human (FIH) trial for the treatment of ovarian cancer, expected in the second half of 2026.

Following the meeting, Ernexa has accelerated key operational activities. Tech transfer – one of the most significant milestones in preparing for clinical manufacturing – is already underway, positioning the company to rapidly advance toward production of clinical-grade material and trial readiness.

“We are very pleased with the outcome of our engagement with the FDA,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “The Agency’s feedback validates our development strategy and gives us the green light to move forward with urgency. With tech transfer now in progress, we are operating at full speed to bring our first-in-human studies online in 2026. This is a major step toward delivering transformative cell therapies to patients with serious and underserved diseases.”

Ernexa is currently advancing two synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies – ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease. Built from reprogrammed induced pluripotent stem cells (iPSCs), Ernexa’s engineered iMSCs are designed to actively home in on tumors or inflamed tissues and deliver potent therapeutic cytokines directly to the disease site. This targeted, off-the-shelf approach aims to overcome key limitations of traditional MSC therapies while enabling scalable manufacturing and broad patient accessibility.

The company’s initial clinical development will focus on ERNA-101 for the treatment of ovarian cancer, a disease with limited effective targeted therapies and high recurrence rates.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s synthetic, allogeneic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

FAQ

What did Ernexa announce about its FDA Pre-IND meeting on Jan 6, 2026 (ERNA)?

Ernexa said the FDA provided regulatory alignment and set a clear pathway toward submitting an IND.

When does Ernexa expect to start the first-in-human ERNA-101 trial for ovarian cancer?

Ernexa expects to initiate the ERNA-101 FIH trial in the second half of 2026.

What operational step is Ernexa undertaking to prepare for clinical trials (ERNA)?

Ernexa has begun tech transfer to enable production of clinical-grade material and trial readiness.

Which programs are in Ernexa's clinical pipeline and which is prioritized (ERNA)?

Ernexa is advancing ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease, prioritizing ERNA-101.

Does Ernexa have clinical data or an active IND for ERNA-101 (ERNA)?

No; the company reported regulatory alignment but said the IND submission and clinical dosing are still pending.